PT-141 for women: what the bremelanotide research shows for female desire
The first injectable approved by the FDA specifically for low desire in premenopausal women — and the only peptide treatment in this category.
TL;DR
- PT-141 (bremelanotide) is the only FDA-approved injectable for low sexual desire in premenopausal women, branded as Vyleesi.
- It acts on a brain receptor that influences desire and arousal — not blood flow.
- Compounded PT-141 is not FDA-approved. Any peptide use requires a licensed clinician evaluation.
What it is
PT-141, also known by its generic name bremelanotide and the brand name Vyleesi, is a short peptide approved by the FDA in 2019 for premenopausal women with HSDD (hypoactive sexual desire disorder — persistent, distressing low sexual desire). It is the first and only on-demand injectable in this category. The branded form is FDA-approved; compounded versions from 503A pharmacies are not FDA-approved.
How it works
Think of arousal and desire as having two different switches in the brain. Most ED medications turn on the plumbing — they improve blood flow. PT-141 reaches for a different switch entirely: a brain receptor called MC4R (melanocortin-4 receptor — a node in the brain's desire-and-arousal circuit). By activating MC4R, PT-141 acts on the wanting side of the equation, not the mechanical side. That is why it can work where blood-flow drugs fall short.
Who asks about it
Women come to this topic after low desire becomes more than a passing season — often a year or longer of feeling disconnected from their own arousal, despite a relationship they want to be in. Many have already tried hormones, counseling, or both. They want to know if a single injectable, taken as needed, fits inside an honest plan.
What the research says
In two large randomized placebo-controlled trials (RECONNECT studies, 24 weeks), bremelanotide produced statistically significant improvements in desire scores and distress scores compared with placebo in premenopausal women with acquired, generalized HSDD (Kingsberg et al., 2019). About 25 percent of women on bremelanotide reported a clinically meaningful improvement in desire — versus about 17 percent on placebo. That is not a small difference, but it is also not "works for everyone."
Most common side effects in those trials: nausea (about 4 in 10 participants), flushing, and headache. A small temporary rise in blood pressure was observed and is the basis for caution in women with uncontrolled hypertension.
What to know before considering it
PT-141 is generally well-tolerated in physician-supervised protocols. Nausea is the most common reason patients discontinue use. Women with uncontrolled hypertension or cardiovascular disease need a careful clinician evaluation before considering it. PT-141 should not be combined with alcohol-heavy evenings — both nausea and blood-pressure effects are amplified. As with any peptide, this requires a licensed clinician.
The Halftime POV
Low desire is one of the most under-discussed shifts in midlife — and one of the most fixable when discussed honestly. PT-141 is not a fix for every cause of low desire. It is a specific tool for a specific subset. The job of a thoughtful clinician is to know which subset you fall into before reaching for any tool.
Related reading:
- The melanocortin system: why PT-141 works at the brain level
- Erectile dysfunction as a vascular health signal
- Peptide therapy risks and contraindications
FAQ
Q: Is PT-141 FDA-approved for women? A: Yes. Bremelanotide (the branded form Vyleesi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded versions are not FDA-approved.
Q: How quickly does PT-141 work? A: Most users report onset within 45 minutes of injection. The window of effect typically lasts a few hours.
Q: What are the most common side effects? A: Nausea, flushing, headache, and short-term blood-pressure elevations are the most commonly reported in clinical trials.
Q: Does PT-141 increase arousal in postmenopausal women? A: The FDA approval is for premenopausal women. Use beyond that population is off-label and requires a clinician evaluation.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
Is PT-141 FDA-approved for women?
Yes. Bremelanotide (the branded form Vyleesi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded versions are not FDA-approved.
How quickly does PT-141 work?
Most users report onset within 45 minutes of injection. The window of effect typically lasts a few hours.
What are the most common side effects?
Nausea, flushing, headache, and short-term blood-pressure elevations are the most commonly reported in clinical trials.
Does PT-141 increase arousal in postmenopausal women?
The FDA approval is for premenopausal women. Use beyond that population is off-label and requires a clinician evaluation.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.